Ascendis Pharma Growth Disorders A/S
CVR number: 32323677
Tuborg Boulevard 12, 2900 Hellerup
Income statement (kEUR)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | -17 880.18 | -30 184.95 | -47 933.48 | -57 035.67 | - 114 185.67 |
| Costs of management | - 117.16 | - 116.20 | - 116.47 | - 116.46 | -30.02 |
| EBIT | -17 997.34 | -30 301.15 | -48 049.95 | -57 152.13 | - 114 215.69 |
| Other financial income | 0.08 | 0.31 | 78.55 | ||
| Other financial expenses | -1 281.93 | -1 858.50 | -3 026.02 | -4 305.04 | -6 259.16 |
| Pre-tax profit | -19 279.19 | -32 159.65 | -51 075.97 | -61 456.86 | - 120 396.30 |
| Income taxes | 253.31 | 61.08 | 118.09 | 75.69 | 172.87 |
| Net earnings | -19 025.88 | -32 098.57 | -50 957.88 | -61 381.17 | - 120 223.43 |
Assets (kEUR)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Intangible rights | 109.09 | 54.55 | |||
| Intangible assets total | 109.09 | 54.55 | |||
| Tangible assets total | |||||
| Participating interests | 6 529.10 | 6 529.10 | 8 439.09 | ||
| Investments total | 6 529.10 | 6 529.10 | 8 439.09 | ||
| Non-current loans receivable | 8 439.09 | 8 439.09 | |||
| Long term receivables total | 8 439.09 | 8 439.09 | |||
| Inventories total | |||||
| Current trade debtors | 53.01 | 39.61 | 180.27 | ||
| Prepayments and accrued income | 637.80 | 205.44 | 30.90 | ||
| Current other receivables | 1 491.15 | 2 036.20 | 1 043.40 | 5 129.23 | |
| Short term receivables total | 2 128.95 | 2 241.64 | 1 096.40 | 5 168.84 | 211.17 |
| Cash and bank deposits | 0.34 | 1 905.39 | 10.51 | 7.45 | 12 971.50 |
| Cash and cash equivalents | 0.34 | 1 905.39 | 10.51 | 7.45 | 12 971.50 |
| Balance sheet total (assets) | 8 767.47 | 10 730.68 | 9 546.00 | 13 615.38 | 21 621.75 |
Equity and liabilities (kEUR)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Share capital | 67.02 | 67.02 | 67.02 | 67.02 | 67.02 |
| Share premium account | -50.27 | -50.27 | |||
| Other reserves | -50.27 | -50.27 | -50.27 | ||
| Retained earnings | -38 376.21 | -57 402.09 | -89 500.66 | - 140 458.54 | - 201 839.72 |
| Profit of the financial year | -19 025.88 | -32 098.57 | -50 957.88 | -61 381.17 | - 120 223.43 |
| Shareholders equity total | -57 385.34 | -89 483.90 | - 140 441.79 | - 201 822.96 | - 322 046.40 |
| Non-current owed to group member | 65 210.72 | 97 208.89 | 149 981.91 | 215 432.42 | 343 661.19 |
| Non-current liabilities total | 65 210.72 | 97 208.89 | 149 981.91 | 215 432.42 | 343 661.19 |
| Other non-interest bearing current liabilities | 942.09 | 3 005.69 | 5.88 | 5.92 | 6.96 |
| Current liabilities total | 942.09 | 3 005.69 | 5.88 | 5.92 | 6.96 |
| Balance sheet total (liabilities) | 8 767.47 | 10 730.68 | 9 546.00 | 13 615.38 | 21 621.75 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.